---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-157374"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-06-07T23:59:59+00:00"
generated_at: "2026-06-01T05:43:10.690766+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma shareholders approve all proposals at 2024 AGM

## Summary
- Quorum of 57.6M shares (64% of eligible) voted; all seven proposals passed.
- Proposal 6 (reappointment of Louis Lange): 34.5M For, 13.2M Against, 357k Abstain.
- Proposal 5 (appointment of William H. Lewis): 48.1M For, 10.7k Against, 1.2k Abstain.
- Adopted 2023 annual accounts, discharged directors, ratified Deloitte as auditor for 2024.
- Item 8.01 refiled a license agreement with Menarini omitted from 2023 10-K.

## SEC filing metadata
- accession: 0001193125-24-157374
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524157374/0001193125-24-157374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524157374/d837571d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-157374
- JSON: https://secwatch.observer/filing/0001193125-24-157374.json
- Plain text: https://secwatch.observer/filing/0001193125-24-157374.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.